Abstract
The ongoing outbreak of the novel coronavirus (COVID-19) started from Wuhan, China, at the end of December 2019. It is one of the leading public health challenges in the world because of high transmissibility. The first patient of COVID-19 was officially reported on March 8, 2020, in Bangladesh. Using the epidemiological data up to October 17, 2020, we try to estimate the infectious size. In this paper, we used Classical SIR (Susceptible-Infected-Recovered), model. The epidemic has now spread to more than 216 countries around the world. The necessary reproduction number R0 of Bangladesh is 1.92. The primary data was collected from the Coronavirus (COVID-19) Dashboard (BANGLADESH: CASE TREND). In our analysis, the statistical parameters specify the best import to provide the predicted result. We projected that the epidemic curve pulling down in Bangladesh will start from the first week of November (November 4, 2020) and may end in the last week of July (July 24, 2021). It is also estimated that the start of acceleration on May 24, 2020, in 53 days, and the start of steady growth on September 10, 2020, in 109 days. The start of the ending phase of the epidemic may appear in the first week of November 2020, and the epidemic is expected to be finished by the last week of July 2021. However, these approximations may become invalid if a large variety of data occurs in upcoming days.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was taken from ethics board of Noakhali Science and Technology University
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be available upon reasonable request
